| First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised … YY Janjigian, K Shitara, M Moehler, M Garrido, P Salman, L Shen, ... The Lancet 398 (10294), 27-40, 2021 | 1713 | 2021 |
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018 | 1674 | 2018 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1168 | 2018 |
| Regulatory T cells in cancer immunosuppression—implications for anticancer therapy Y Togashi, K Shitara, H Nishikawa Nature reviews Clinical oncology 16 (6), 356-371, 2019 | 1154 | 2019 |
| Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer K Shitara, YJ Bang, S Iwasa, N Sugimoto, MH Ryu, D Sakai, HC Chung, ... New England Journal of Medicine 382 (25), 2419-2430, 2020 | 919 | 2020 |
| Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 … K Shitara, E Van Cutsem, YJ Bang, C Fuchs, L Wyrwicz, KW Lee, ... JAMA oncology 6 (10), 1571-1580, 2020 | 834 | 2020 |
| PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer T Kamada, Y Togashi, C Tay, D Ha, A Sasaki, Y Nakamura, E Sato, ... Proceedings of the National Academy of Sciences 116 (20), 9999-10008, 2019 | 808 | 2019 |
| Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603) S Fukuoka, H Hara, N Takahashi, T Kojima, A Kawazoe, M Asayama, ... Journal of Clinical Oncology 38 (18), 2053-2061, 2020 | 599 | 2020 |
| The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies S Kumagai, Y Togashi, T Kamada, E Sugiyama, H Nishinakamura, ... Nature immunology 21 (11), 1346-1358, 2020 | 573 | 2020 |
| Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an … PC Thuss-Patience, MA Shah, A Ohtsu, E Van Cutsem, JA Ajani, H Castro, ... The lancet oncology 18 (5), 640-653, 2017 | 511 | 2017 |
| The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer YY Janjigian, A Kawazoe, P Yañez, N Li, S Lonardi, O Kolesnik, ... Nature 600 (7890), 727-730, 2021 | 481 | 2021 |
| BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer T Yokota, T Ura, N Shibata, D Takahari, K Shitara, M Nomura, C Kondo, ... British journal of cancer 104 (5), 856-862, 2011 | 459 | 2011 |
| Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial K Shitara, T Doi, M Dvorkin, W Mansoor, HT Arkenau, A Prokharau, ... The Lancet Oncology 19 (11), 1437-1448, 2018 | 443 | 2018 |
| Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or … T Doi, K Shitara, Y Naito, A Shimomura, Y Fujiwara, K Yonemori, ... The Lancet Oncology 18 (11), 1512-1522, 2017 | 420 | 2017 |
| Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal … YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh, HC Chung, KW Lee, T Omori, ... The Lancet Oncology 23 (2), 234-247, 2022 | 391 | 2022 |
| Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments S Kumagai, S Koyama, K Itahashi, T Tanegashima, Y Lin, Y Togashi, ... Cancer Cell 40 (2), 201-218. e9, 2022 | 366 | 2022 |
| Assessment of pembrolizumab therapy for the treatment of microsatellite instability–high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE … J Chao, CS Fuchs, K Shitara, J Tabernero, K Muro, E Van Cutsem, ... JAMA oncology 7 (6), 895-902, 2021 | 279 | 2021 |
| LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal … M Moehler, K Shitara, M Garrido, P Salman, L Shen, L Wyrwicz, ... Annals of Oncology 31, S1191, 2020 | 251 | 2020 |
| Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer K Shitara, JA Ajani, M Moehler, M Garrido, C Gallardo, L Shen, ... Nature 603 (7903), 942-948, 2022 | 246 | 2022 |
| Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction … K Shitara, F Lordick, YJ Bang, P Enzinger, D Ilson, MA Shah, ... The Lancet 401 (10389), 1655-1668, 2023 | 237 | 2023 |
